RxDoctor Payments DataLook up a doctor →

Stephen Threadgill, MD

Gastroenterology · Oxford, MSNPI 1225046543

Payments from drug & device makers

$9,451in general payments, 2019–2025

Across 499 payments — averaging $18.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Johnson & Johnson$856
  • Pfizer$655
  • Lilly USA, LLC$562
  • Takeda Pharmaceuticals U.S.A., Inc.$533
  • plus $4K from 35 others

What the payments were for

  • Food & beverage$9,19497%
  • Education$1892%
  • Gifts$691%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,451 in reported general payments places this provider in the 70th percentile of 127 gastroenterology providers in Mississippi.

See all gastroenterology providers in Mississippi

Medicare billing

Part B allowed, 2024
$375,338
Medicare patients
797
Services billed
10,152

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OcalivaObeticholic Acid12$107,173
LinzessLinaclotide104$78,500
CreonLipase/Protease/Amylase19$33,864
Pantoprazole Sodium1,601$21,287
Misoprostol229$18,354
Famotidine935$16,878
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates246$16,010
ClenpiqSod Picosulf/Mag Ox/Citric Ac66$11,164
Colestipol Hcl85$6,746
Dexlansoprazole DrDexlansoprazole31$6,313
Omeprazole645$6,152
Mesalamine ErMesalamine17$6,121
GemtesaVibegron13$5,921
Ondansetron OdtOndansetron246$4,166
Sucralfate55$4,139

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$1,489$112,364123 claims
Intercept Pharmaceuticals, Inc.Ocaliva$258$107,17312 claims
Ferring Pharmaceuticals Inc.Clenpiq$32$11,16466 claims
Braintree Laboratories, Inc.Sutab$149$2,64416 claims
SandozLansoprazole$24$79043 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 127 gastroenterology providers in Mississippi.

Other gastroenterology in Oxford

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →